Trial Profile
A Double Blind, Placebo Controlled, Randomized, Multicenter Study Evaluating The Efficacy And Safety Of Eighteen Months Of Treatment With PF 04494700 (TTP488) In Participants With Mild To Moderate Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Oct 2019
Price :
$35
*
At a glance
- Drugs Azeliragon (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 15 Jul 2019 According to vTv Therapeutics media release, data from this study will be presented at the 2019 Alzheimer's Association International Conference (AAIC) held in Los Angeles, California, July 14 to 18, 2019.
- 01 Jun 2017 According to a vTv Therapeutics media release, data from part A are expected to read out in early 2018 while data from part B are expected to read out in late 2018.
- 07 Sep 2016 Results published in the Media Release